Bridge Biotherapeutics' ulcerative colitis drug fails Phase II trial; biotech plans to push forward

South Korean biotech Bridge Biotherapeutics announced Monday that its mid-stage trial for an ulcerative colitis drug failed.

The biotech said that …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bridge Bio­ther­a­peu­tic­s' ul­cer­a­tive col­i­tis drug fails Phase II tri­al; biotech plans to push for­ward